1. 1. de Bono JS, Oudard S, Ozguroglu M, Hansen S, Machiels JP, Kocak I, Gravis G, Bodrogi I, Mackenzie MJ, Shen L, Roessner M, Gupta S, Sartor AO, TROPIC Investigators: Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial. Lancet 2010; 376: 1147–1154. , DOI:doi:10.1016/S0140-6736(10)61389-XPMID:20888992
2. 2. Oken MM, Creech RH, Tormey DC, Horton J, Davis TE, McFadden ET, Carbone PP: Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 1982; 5: 649–655. , DOI:doi:10.1097/00000421-198212000-00014PMID:7165009
3. 3. Gandaglia G, Abdollah F, Schiffmann J, Trudeau V, Shariat SF, Kim SP, Perrotte P, Montorsi F, Briganti A, Trinh QD, Karakiewicz PI, Sun M: Distribution of metastatic sites in patients with prostate cancer: A population-based analysis. Prostate 2014; 74: 210–216. , doPMID:24132735, DOI:10.1002/pros.22742
4. 4. Hatzoglou V, Patel GV, Morris MJ, Curtis K, Zhang Z, Shi W, Huse J, Rosenblum M, Holodny AI, Young RJ: Brain metastases from prostate cancer: an 11-year analysis in the MRI era with emphasis on imaging characteristics, incidence, and prognosis. J Neuroimaging 2014; 24: 161–166. , doPMID:23279641, DOI:10.1111/j.1552-6569.2012.00767.x
5. 5. Tremont-Lukats IW, Bobustuc G, Lagos GK, Lolas K, Kyritsis AP, Puduvalli VK: Brain metastasis from prostate carcinoma: The M. D. Anderson Cancer Center experience. Cancer 2003; 98: 363–368. , doPMID:12872358, DOI:10.1002/cncr.11522